Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Chong

Showing results (331-340 of 348) with videos related to

Pageof 35
Sort By:
Nature Communications|May 15, 2026
Naïve CD4<sup>+</sup> T-cells and disease status at CART infusion correlate with clinical outcomes in real-world large B-cell lymphoma patients receiving second-line CAR T therapyMichael Schneider, Luca Paruzzo, Federico Stella, et al.
Cancer Discovery|July 29, 2022
Modulation of BCL-2 in Both T Cells and Tumor Cells to Enhance Chimeric Antigen Receptor T-cell Immunotherapy against CancerYong Gu Lee, Puneeth Guruprasad, Guido Ghilardi, et al.
The New England Journal of Medicine|May 7, 2025
Enhanced CAR T-Cell Therapy for Lymphoma after Previous FailureJakub Svoboda, Daniel J Landsburg, James Gerson, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 26, 2019
Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular TherapyTania Jain, Merav Bar, Ankit J Kansagra, et al.
Nature Medicine|January 24, 2024
T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapyGuido Ghilardi, Joseph A Fraietta, James N Gerson, et al.
Plos One|September 3, 2011
Is chytridiomycosis an emerging infectious disease in Asia?Andrea Swei, Jodi J L Rowley, Dennis Rödder, et al.
Blood Advances|April 9, 2025
Bridging Radiotherapy Prior to Chimeric Antigen Receptor T-Cells for B-Cell Lymphomas: An ILROG Multicenter StudyNikhil Yegya-Raman, John P Plastaras, Christopher M Wright, et al.
Blood Advances|June 23, 2022
Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimenMeghan C Thompson, Rosemary A Harrup, Catherine C Coombs, et al.
Blood Advances|August 5, 2025
Treatment and outcomes of progression of disease post-CAR T-cell therapy in mantle cell lymphoma: a multicenter analysisZachary D Epstein-Peterson, Anath Christopher Lionel, Ashlee Joseph, et al.
The Journal of Infectious Diseases|July 25, 2024
Immunologic Predictors of Vaccine Responsiveness in Patients With Lymphoma and Chronic Lymphocytic LeukemiaElise A Chong, Kingsley Gideon Kumashie, Emeline R Chong, et al.
Pageof 35

Showing results (331-340 of 348) with videos related to

Sort By:
Pageof 35
Nature Communications|May 15, 2026
Naïve CD4<sup>+</sup> T-cells and disease status at CART infusion correlate with clinical outcomes in real-world large B-cell lymphoma patients receiving second-line CAR T therapyMichael Schneider, Luca Paruzzo, Federico Stella, et al.
Cancer Discovery|July 29, 2022
Modulation of BCL-2 in Both T Cells and Tumor Cells to Enhance Chimeric Antigen Receptor T-cell Immunotherapy against CancerYong Gu Lee, Puneeth Guruprasad, Guido Ghilardi, et al.
The New England Journal of Medicine|May 7, 2025
Enhanced CAR T-Cell Therapy for Lymphoma after Previous FailureJakub Svoboda, Daniel J Landsburg, James Gerson, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 26, 2019
Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular TherapyTania Jain, Merav Bar, Ankit J Kansagra, et al.
Nature Medicine|January 24, 2024
T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapyGuido Ghilardi, Joseph A Fraietta, James N Gerson, et al.
Plos One|September 3, 2011
Is chytridiomycosis an emerging infectious disease in Asia?Andrea Swei, Jodi J L Rowley, Dennis Rödder, et al.
Blood Advances|April 9, 2025
Bridging Radiotherapy Prior to Chimeric Antigen Receptor T-Cells for B-Cell Lymphomas: An ILROG Multicenter StudyNikhil Yegya-Raman, John P Plastaras, Christopher M Wright, et al.
Blood Advances|June 23, 2022
Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimenMeghan C Thompson, Rosemary A Harrup, Catherine C Coombs, et al.
Blood Advances|August 5, 2025
Treatment and outcomes of progression of disease post-CAR T-cell therapy in mantle cell lymphoma: a multicenter analysisZachary D Epstein-Peterson, Anath Christopher Lionel, Ashlee Joseph, et al.
The Journal of Infectious Diseases|July 25, 2024
Immunologic Predictors of Vaccine Responsiveness in Patients With Lymphoma and Chronic Lymphocytic LeukemiaElise A Chong, Kingsley Gideon Kumashie, Emeline R Chong, et al.
Pageof 35